Innovative and Emerging Trials in Ovarian Cancer

Поделиться
HTML-код
  • Опубликовано: 17 окт 2024
  • Innovative and Emerging Trials in Ovarian Cancer
    Speaker: Dr. Diane Yamada
    Chief, Gynecologic Oncology, UChicago Medicine

Комментарии • 3

  • @viorelscrob6391
    @viorelscrob6391 Год назад

    When is recomended the treatment with a single agent. ..?

    • @shetlandsheep3081
      @shetlandsheep3081 Год назад

      I had single agent carboplatin and it was because I had a severe hyperallergic reaction to paclitaxil. They could not risk doing the usual toleration process because the reaction was too severe.

    • @viorelscrob6391
      @viorelscrob6391 Год назад

      @@shetlandsheep3081 Oh okay. And for my mom was made tratament with a single agent only. ...but she was not alergic to "Paclitaxel." ..i not understand why. .....where your from. .?